Jean-François Franetich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jean-François Franetich has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Dominique Mazier
Sorbonne Université, INSERM, CNRS, Centre d’Immunologie et des Maladies Infectieuses, CIMI, 75013 Paris, France
3 shared publications - Robert W. Sauerwein
Radboud University Medical Center
2 shared publications - Shahin Tajeri
Laboratoire de Biologie des Apicomplexes, Faculté de Médecine, Université Paris Descartes - Sorbonne Paris Cité, Paris, France; INSERM U1016, CNRS UMR8104, Cochin Institute, Paris, France; Freie Universität Berlin, Institute for Parasitology and Tropical Veterinary Medicine, Berlin, Germany; Freie Universität Berlin, Veterinary Centre for Resistance Research, Berlin, Germany
2 shared publications - Amélie Vantaux
Malaria Molecular Epidemiology Unit, Institute Pasteur of Cambodia
1 shared publication - Anne-Marie Zeeman
Department of Parasitology, Biomedical Primate Research Centre
1 shared publication Anthony Siau
Université Pierre et Marie Curie
1 shared publication
Latest Publications
- Open Access
- 15 February 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 63 (5) , 107112
Azithromycin disrupts apicoplast biogenesis in replicating and dormant liver stages of the relapsing malaria parasites Plasmodium vivax and Plasmodium cynomolgi
- 15 February 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 63 (5) , 107112
Open AccessAzithromycin disrupts apicoplast biogenesis in replicating and dormant liver stages of the relapsing malaria parasites Plasmodium vivax and Plasmodium cynomolgi
- Open Access
Artemisinin-independent inhibitory activity of Artemisia sp. infusions against different Plasmodium stages including relapse-causing hypnozoites
Artemisinin-based combination therapies (ACT) are the frontline treatments against malaria worldwide. Recently the use of traditional infusions from Artemisia annua (from which artemisinin is obtained) or A. afra (lacking artemisinin) has been controversially advocated. Such unregulated plant-based remedies are strongly discouraged as they might constitute sub-optimal therapies and promote drug resistance. Here, we conducted the first comparative study of the anti-malarial effects of both plant infusions in vitro against the asexual erythrocytic stages of P. falciparum and the pre-erythrocytic (i. e., liver) stages of various Plasmodium species. Low concentrations of either infusion accounted for significant inhibitory activities across every parasite species and stage studied. We show that these antiplasmodial effects were essentially artemisinin-independent and were additionally monitored by observations of the parasite apicoplast and mitochondrion. In particular, the infusions significantly incapacitated sporozoites, and for P. vivax and P. cynomolgi, disrupted the hypnozoites. This provides the first indication that compounds other than 8-aminoquinolines could be effective antimalarials against relapsing parasites. These observations advocate for further screening to uncover urgently needed novel antimalarial lead compounds.
Open AccessArtemisinin-independent inhibitory activity of Artemisia sp. infusions against different Plasmodium stages including relapse-causing hypnozoites
Artemisinin-based combination therapies (ACT) are the frontline treatments against malaria worldwide. Recently the use of traditional infusions from Artemisia annua (from which artemisinin is obtained) or A. afra (lacking artemisinin) has been controversially advocated. Such unregulated plant-based remedies are strongly discouraged as they might constitute sub-optimal therapies and promote drug resistance. Here, we conducted the first comparative study of the anti-malarial effects of both plant infusions in vitro against the asexual erythrocytic stages of P. falciparum and the pre-erythrocytic (i. e., liver) stages of various Plasmodium species. Low concentrations of either infusion accounted for significant inhibitory activities across every parasite species and stage studied. We show that these antiplasmodial effects were essentially artemisinin-independent and were additionally monitored by observations of the parasite apicoplast and mitochondrion. In particular, the infusions significantly incapacitated sporozoites, and for P. vivax and P. cynomolgi, disrupted the hypnozoites. This provides the first indication that compounds other than 8-aminoquinolines could be effective antimalarials against relapsing parasites. These observations advocate for further screening to uncover urgently needed novel antimalarial lead compounds.
- 21 June 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (395)
Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers
Infectivity of P. falciparum sporozoites determines the course of primary malaria infection in human volunteers.
- 21 June 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (395)
Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers
Infectivity of P. falciparum sporozoites determines the course of primary malaria infection in human volunteers.
- 12 February 2004
- Published by Springer Nature in Parasitology Research
- Vol. 92 (6) , 449-452
Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle
The CSP, EMP2/MESA, MSP2, MSP3, MSP5, RAP1, RAP2, RESA1, SERA1 and SSP2/TRAP genes of Plasmodium falciparum are vaccine candidates. The hepatic phase of the infection is of major interest due to the protection induced by immunization with radiation-attenuated sporozoites. We therefore performed RT-PCR experiments to determine whether these genes are transcribed during this phase. Whereas transcripts of the CSP gene were detectable only in sporozoites, transcripts of the MSP2, MSP5, RAP1, RAP2, SERA1 and SSP2/TRAP genes were present in both sporozoites and infected hepatocytes. Transcripts of the EMP2/MESA gene were detectable only in infected hepatocytes. Transcripts of the MSP3 and RESA1 genes were not detectable in sporozoites or in infected hepatocytes. Genes presently identified as being transcribed during the hepatic phase may be of interest with respect to the design of preventative vaccination strategies.
- 12 February 2004
- Published by Springer Nature in Parasitology Research
- Vol. 92 (6) , 449-452
Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle
The CSP, EMP2/MESA, MSP2, MSP3, MSP5, RAP1, RAP2, RESA1, SERA1 and SSP2/TRAP genes of Plasmodium falciparum are vaccine candidates. The hepatic phase of the infection is of major interest due to the protection induced by immunization with radiation-attenuated sporozoites. We therefore performed RT-PCR experiments to determine whether these genes are transcribed during this phase. Whereas transcripts of the CSP gene were detectable only in sporozoites, transcripts of the MSP2, MSP5, RAP1, RAP2, SERA1 and SSP2/TRAP genes were present in both sporozoites and infected hepatocytes. Transcripts of the EMP2/MESA gene were detectable only in infected hepatocytes. Transcripts of the MSP3 and RESA1 genes were not detectable in sporozoites or in infected hepatocytes. Genes presently identified as being transcribed during the hepatic phase may be of interest with respect to the design of preventative vaccination strategies.